Last updated: December 6, 2023
Sponsor: Nanjing First Hospital, Nanjing Medical University
Overall Status: Active - Recruiting
Phase
1/2
Condition
N/ATreatment
Amoxicillin combined with vonoprazan and fucoidan
Amoxicillin combined with vonoprazan
Clinical Study ID
NCT05461508
KY20220518-02-KS-01
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18-65 years old;
- Patients diagnosed as HP positive;
- Patients who have not received HP eradication treatment in the past, or who havefailed in the early eradication but have not received eradication treatment withinhalf a year;
- Voluntarily participate in this trial and sign the informed consent form.
Exclusion
Exclusion Criteria:
- Allergic to the study drug (penicillin allergy, etc.);
- Patients with chronic gastritis and peptic ulcer;
- Patients who have received HP eradication treatment within half a year;
- Antibiotics and bismuth agents were used 4 weeks before the start of the studytreatment, and histamine H2 receptor antagonists or PPIs were used 2 weeks before thestart of the study treatment;
- Use adrenocortical hormones, non steroidal anti-inflammatory drugs or anticoagulants;
- History of esophageal or gastric surgery;
- Pregnant and lactating women;
- Suffering from serious accompanying diseases, such as liver disease, cardiovasculardisease, lung disease, kidney disease;
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Amoxicillin combined with vonoprazan and fucoidan
Phase: 1/2
Study Start date:
October 01, 2022
Estimated Completion Date:
July 31, 2024
Study Description
Connect with a study center
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu 210000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.